Janux Therapeutics, Inc. (JANX) Operating income 2020–2025
Janux Therapeutics, Inc. (JANX) annual operating income history from SEC filings — each fiscal year as reported.
-$157.7MFY2025 · since FY2020: -$4.8M → -$157.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$157.7M | -59.5% |
| FY2024 | -$98.8M | -35.4% |
| FY2023 | -$73.0M | -8.8% |
| FY2022 | -$67.1M | -103.7% |
| FY2021 | -$32.9M | -579.9% |
| FY2020 | -$4.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More JANX financial trends
JANX RevenueJANX Net incomeJANX Net marginJANX Gross profitJANX Gross marginJANX Operating marginJANX Operating cash flowJANX Free cash flowJANX Capital expendituresJANX Return on equityJANX Stock buybacksJANX Dividends paidJANX Total assetsJANX Total liabilitiesJANX Shareholders’ equityJANX overview →